Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000572522 | SCV000667853 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-02-16 | criteria provided, single submitter | clinical testing | The c.456G>T variant (also known as p.V152V), located in coding exon 4 of the ATM gene, results from a G to T substitution at nucleotide position 456. This nucleotide substitution does not change the at codon 152. This nucleotide position is well conserved through mammals. In silico splice site analysis for this alteration is inconclusive but there is a slight weakening of the native donor site; however, direct evidence is insufficient at this time (Ambry internal data). Based on the available evidence, the clinical significance of this alteration remains unclear. |
Color Diagnostics, |
RCV000572522 | SCV001354053 | likely benign | Hereditary cancer-predisposing syndrome | 2020-01-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001500810 | SCV001705610 | likely benign | Ataxia-telangiectasia syndrome | 2023-08-27 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV004592710 | SCV005085223 | benign | Familial cancer of breast | 2024-04-19 | criteria provided, single submitter | clinical testing | This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. |